ArticleThe Journal of investigative dermatology2017
Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.
Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Intravenous immunoglobulin for the treatment of morphea in pediatric patients: A case series.JAAD case reports · 2026Article
- Pembrolizumab-Induced Morphea in a Patient With Metastatic Urothelial Carcinoma.Case reports in urology · 2026Article
- Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis.The British journal of dermatology · 2025Article
- Unique and shared transcriptomic signatures underlying localized scleroderma pathogenesis identified using interpretable machine learning.JCI insight · 2025Article
- What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.Journal of clinical medicine · 2024Review
- Characterization of Endothelial Cell Subclusters in Localized Scleroderma Skin with Single-Cell RNA Sequencing Identifies NOTCH Signaling Pathway.International journal of molecular sciences · 2024Article
- Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.International journal of molecular sciences · 2024Article
- Senomorphic activity of a combination of niacinamide and hyaluronic acid: correlation with clinical improvement of skin aging.Scientific reports · 2024Article
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?Frontiers in immunology · 2024Review
- IL-6 trans-signaling in a humanized mouse model of scleroderma.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Unravelling morphoea aetiopathogenesis by next-generation sequencing of paired skin biopsies.Archives of dermatological research · 2023Article
- Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis.JCI insight · 2023Article
- Single-Cell Transcriptome Analysis Identifies Subclusters with Inflammatory Fibroblast Responses in Localized Scleroderma.International journal of molecular sciences · 2023Article
- Development and function of tissue-resident memory B cells.Advances in immunology · 2022Article
- The Immunogenetics of Morphea and Lichen Sclerosus.Advances in experimental medicine and biology · 2022Review
- Upcoming treatments for morphea.Immunity, inflammation and disease · 2021Review
- Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor.Aging · 2021Article
- Morphea: progress to date and the road ahead.Annals of translational medicine · 2021Review
- Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin.Frontiers in pediatrics · 2021Article
- Single-cell transcriptome conservation in a comparative analysis of fresh and cryopreserved human skin tissue: pilot in localized scleroderma.Arthritis research & therapy · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
IFN-related pathways have not been studied in morphea, and biomarkers are needed. We sought to characterize morphea serum cytokine imbalance and IFN-related gene expression in blood and skin to address this gap by performing a case-control study of 87 participants with morphea and 26 healthy control subjects. We used multiplexed immunoassays to determine serum cytokine concentrations, performed transcriptional profiling of whole blood and lesional morphea skin, and used double-staining immunohistochemistry to determine the cutaneous cellular source of CXCL9. We found that CXCL9 was present at increased concentrations in morphea serum (P < 0.0001), as were other T helper type 1 cytokines. CXCL9 serum concentration correlated with the modified Localized Scleroderma Skin Severity Index (r = 0.44, P = 0.0001), a validated measure of disease activity. CXCL9 gene expression was also increased in inflammatory lesional morphea skin (fold change = 30.6, P = 0.006), and preliminary transcriptional profiling showed little evidence for IFN signature in whole blood. Double-staining immunohistochemistry showed CXCL9 co-localized with CD68
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.